METABOLIC / SINGLE
SEMAGLUTIDE
2MG · 5MG · 10MG · 15MG · 20MG · 30MGThis content is intended for educational and research reference only and does not constitute medical advice, diagnosis, or treatment. Experimental compounds are for research use only and are not for human consumption. Always consult qualified healthcare providers before starting any therapy.
Research Overview
A GLP-1 receptor agonist with high sequence homology to native human GLP-1, studied in glucose regulation and appetite-signalling research.
Available Strengths
- 2MG (SM2)
- 5MG (SM5)
- 10MG (SM10)
- 15MG (SM15)
- 20MG (SM20)
- 30MG (SM30)
Research Protocol
Reference five-stage titration
| Period | Dose | U-100 units | Volume |
|---|---|---|---|
| Weeks 1–4 | 0.25 mg | 7.5 | 0.075 mL |
| Weeks 5–8 | 0.5 mg | 15 | 0.15 mL |
| Weeks 9–12 | 1 mg | 30 | 0.3 mL |
| Weeks 13–16 | 1.7 mg | 51 | 0.51 mL |
| Weeks 17+ (maintenance) | 2.4 mg | 72 | 0.72 mL |
Reconstitution
≈3.33 mg/mL once reconstituted
- Draw 3.0 mL of bacteriostatic water per 10 mg vial.
- Inject slowly along the vial wall; swirl gently until dissolved.
Research context
Studied for reducing appetite, slowing gastric emptying and supporting glucose-dependent insulin secretion; an approximately seven-day half-life supports once-weekly dosing in the reference protocol.
Storage
−20°C before reconstitution. 2–8°C, protected from light, use within 28 days, avoid freeze-thaw cycles.
Research Notes
- For educational and research reference only. Not medical advice and not intended for unsupervised human use.
- Approved semaglutide medicines use fixed proprietary formulations; this research vial is not interchangeable with them.
References
Source reference: PeptideDosages.com · 2026-08-18 · Exact strength match with the cited source